Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns
Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...
Company
Everest Medicines Secures IND Review for Zetomipzomib in China
Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...
Sunshine Guojian’s SSGJ-608 Meets Phase III Efficacy Endpoints in Psoriasis Trial
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc. (HKG: 1530), has announced...
Novartis Invests USD 86.4 Million in New Radiotherapy Facility in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD...
AbbVie to Acquire ImmunoGen for USD 10.1 Billion, Expanding Oncology Portfolio
AbbVie (NYSE: ABBV) has reached an agreement to acquire fellow U.S. biotech ImmunoGen (NASDAQ: IMGN)...
Akeso Biopharma Files New Indication for Penpulimab in First-Line NPC Treatment
Akeso Biopharma (HKG: 9926) has announced a new indication filing for its programmed death-1 (PD-1)...
SanegeneBio Secures Over USD 80 Million in Series A+ Funding to Advance RNAi Therapeutics
SanegeneBio, a Suzhou-based developer of RNA interference (RNAi) therapeutics, has successfully raised over USD 80...
Shanghai Junshi’s Loqtorzi Enters Australian Market Approval Process for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the Therapeutic Goods...
CARsgen Therapeutics Secures U.S. FDA Approval for CT071 Clinical Trials in Multiple Myeloma
CARsgen Therapeutics Holdings Ltd (HKG: 2171), based in China, has announced that it has received...
Lepu Biotechnology’s MRG003 Gains Fast-Track Status from U.S. FDA for Nasopharyngeal Carcinoma
Lepu Biotechnology Co., Ltd (HKG: 2157), based in China, has announced that its flagship product...
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration...
Concentra Biosciences Targets China-Based Biotech LianBio in Unsolicited Takeover Bid
LianBio (OTCMKTS: LIANY), a China-based biotech firm, has become the target of an unsolicited takeover...
Bayer Partners with CrossBay Medical to Enhance Hormonal IUS Delivery System
Germany’s Bayer (ETR: BAYN) has announced a strategic partnership with women’s health innovator CrossBay Medical...
Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions
Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar...
MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion...
Akeso’s AK111 Achieves Key Efficacy Milestones in Phase III Trial for Plaque Psoriasis
Akeso Biopharma (HKG: 9926), based in China, has announced that its pivotal Phase III clinical...
Sichuan Kelun-Biotech to Present Promising Phase II Results for SKB264 in mTNBC at SABCS 2023
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...
TG ImmunoPharma Secures U.S. FDA IND Approval for Promising mAb TGI-5 Targeting Multiple Cancers
TG ImmunoPharma Co., Ltd, based in China, has announced that it has received Investigational New...
Insilico Medicine Launches Clinical Study for First-in-Class PHD Inhibitor ISM5411 in IBD
Insilico Medicine, a China-based biotech leveraging generative artificial intelligence (AI), has announced the initiation of...